Study for early diagnosis of pancreatic cancer
This autumn, CZECRIN and the Masaryk Institute of Oncology (MOU) established a cooperation with Lipidica, a.s.
Together they will participate in the implementation of a study on the functional suitability of the LDPC lipidomic test for early diagnosis of pancreatic cancer. The aim of the study is to validate the sensitivity and specificity of the test, which could be used in routine practice in screening programmes for people at increased risk of cancer after successful completion of the study and obtaining the CE mark.
The study will take place in 12 centres in the Czech Republic.
Lipidica, a.s. develops effective, laboratory-based, non-invasive and early diagnosis of malignant neoplasms. It relies on basic research in the use of lipidome analysis, coupled with mathematical modeling and artificial intelligence algorithms.
